Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.71 |
| ▸ | INSR | P06213 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | MLNR | O43193 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607051 | 0.93 | EGFR (0.73) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL18607356 | 0.93 | EGFR (0.61) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL14718496 | 0.92 | EGFR (0.81) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL18607047 | 0.89 | EGFR (0.84) | EGFRKCNH2IGF1R | |
| SCHEMBL14719316 | 0.86 | EGFR (0.79) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL14719282 | 0.86 | EGFR (0.79) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL18606909 | 0.86 | EGFR (0.63) | EGFRKCNH2IGF1R | |
| SCHEMBL19337054 | 0.85 | EGFR (0.77) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL28942132 | 0.85 | EGFR (0.71) | EGFRINSRKCNH2MLNRKDM1A | |
| SCHEMBL19336979 | 0.85 | EGFR (0.83) | EGFRINSRKCNH2MLNRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885INSR 518/4885KCNH2 3103/4885 |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | ERBB2, EGFR, ERBB3 | EGFR 2/4885INSR 448/4885KCNH2 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.